Last update 21 Nov 2024
SHR-1918
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism ANGPTL3 inhibitors(Angiopoietin like 3 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Login to view timeline
Related
8
Clinical Trials associated with SHR-1918An Efficacy, Safety Study to Evaluate Multiple Subcutaneous SHR-1918 in Combination With Lipid-Lowering Drugs for the Stable Treatment of Hyperlipidemic Patients With Poor Lipid Control-A Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Study
评价多次皮下注射SHR-1918注射液联合降脂药稳定治疗血脂控制不佳的高脂血症患者的有效性、安全性研究—多中心、随机、双盲、安慰剂平行对照的Ⅱ期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of multiple subcutaneous injections of SHR-1918 injection combined with lipid-lowering drugs in the stable treatment of hyperlipidemia patients with poor blood lipid control
A Single-Arm, Open-Label, Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
100 Clinical Results associated with SHR-1918
Login to view more data
100 Translational Medicine associated with SHR-1918
Login to view more data
100 Patents (Medical) associated with SHR-1918
Login to view more data
100 Deals associated with SHR-1918
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Homozygous familial hypercholesterolemia | Phase 2 | - | 24 Sep 2023 | |
| Hyperlipoproteinemia Type II | Phase 2 | CN | 17 Aug 2023 | |
| Hyperlipoproteinemia Type II | Phase 2 | CN | 17 Aug 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05432544 (NEWS) Manual  | Phase 1 | - | (fmjrthuprp) = 300mg及以上剂量水平的LDL-C降低超过30%，持续64天以上，最高达49.1%。 bfezsmygzu (mqyutvagqg ) View more | Positive | 06 Sep 2024 | ||
Not Applicable | - | - | ropeekueyr(pbcdstiikk) = Treatment-emergent adverse events (TEAEs) were reported in 49 (90.7%) subjects in the SHR-1918 group and 17 (94.4%) subjects in the placebo group. The most common TEAEs were upper respiratory tract infection (25.9% with SHR-1918 vs. 27.8% with placebo), protein urine present (22.2% vs. 22.2%), and blood uric acid increased (16.7% vs. 16.7%). All TEAEs were mild or moderate in severity. There were no serious adverse events or TEAEs leading to death. synnpijwep (bkawpngsua ) View more | - | 01 Sep 2024 | ||
Placebo |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free